晚期HER2阳性乳腺癌患者的治疗：当前证据和未来展望

赵 得武1, 李 一鸣1, 朱 海宏2
1、青海大学研究生院
2、青海省人民医院普外科

摘要


15-20%的侵袭性乳腺癌中可发现 ERBB2（编码HER2的基因）的扩增和 /或过度表达，并且与侵袭性表型
和不良临床结果相关。分子生物学和药物开发的不懈研究努力已实施多种HER2靶向疗法，包括单克隆抗体、酪氨
酸激酶抑制剂和抗体-药物偶联物，构成了肿瘤学从实验室到临床转化的最佳例子之一。每种类别药物使用后都改
善了患者的预后，重要的是，不同HER2靶向疗法的组合和顺序使用提高了早期疾病的治愈率，并大大延长了晚期
疾病患者的生存期。本综述将讨论与曲妥珠单抗协同作用的新型靶向药物的开发进展，以及化疗与曲妥珠单抗结合
后可选择性地作用于癌细胞的新型抗体-药物共轭物的开发进展。在这篇文章中，我们回顾了目前可用的临床数据，
这些数据为在使用百妥珠单抗、曲妥珠单抗和紫杉类药物进行标准一线治疗后如何有效治疗HER2阳性乳腺癌，以
及如何治疗已接受过这些药物和T-DM1治疗的早期乳腺癌（EBC）患者的复发提供了信息。此外，我们还讨论了正
在进行临床试验的新型抗HER2靶向药物和组合，这些药物将来可能会被纳入标准治疗范例。

关键词


晚期乳腺癌；抗体药物共轭物；中枢神经系统；HER2-阳性；抗药性；老年病综合评估

全文:

PDF


参考


[1]Choong GM, Cullen GD, O’Sullivan CC. Evolving

standards of care and new challenges in the management of

HER2-positive breast cancer. CA Cancer J Clin. 2020 Sep

2020;70(5):355-374.

[2]Guo L, Shao W, Zhou C, et al. Neratinib for HER2-

positive breast cancer with an overlooked option. Mol Med.

2023 Oct 6 2023;29(1):134.

[3]Barton MK. Mastectomy and breast-conserving

therapy confer equivalent outcomes in young women with

early-stage breast cancer. CA Cancer J Clin. 2015 Sep-Oct

2015;65(5):335-336.

[4]王英哲，殷咏梅，江泽飞.2023年 CSCO《乳腺

癌诊疗指南》更新要点解读.中国肿瘤外科杂志.2023；

15（3）：209-213，218.

[5]中国抗癌协会乳腺癌诊治指南与规范（2013

版）.中国癌症杂志.2013（8）：637-684.

[6]Gianni L, Eiermann W, Semiglazov V, et al.

Neoadjuvant chemotherapy with trastuzumab followed by

adjuvant trastuzumab versus neoadjuvant chemotherapy alone,

in patients with HER2-positive locally advanced breast

cancer (the NOAH trial): a randomised controlled superiority

trial with a parallel HER2-negative cohort. Lancet. 2010 Jan

30 2010;375(9712):377-384.

[7]Huober J, Barrios CH, Niikura N, et al. Atezolizumab

With Neoadjuvant Anti-Human Epidermal Growth Factor

Receptor 2 Therapy and Chemotherapy in Human Epidermal

Growth Factor Receptor 2-Positive Early Breast Cancer:

Primary Results of the Randomized Phase III IMpassion050

Trial. J Clin Oncol. 2022 Sep 1 2022;40(25):2946-2956.

[8]Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and

Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for

Patients With Early or Locally Advanced ERBB2-Positive

Breast Cancer in Asia: The PEONY Phase 3 Randomized

161

现代医学前沿 | 第2卷/第11期

Advances in Mordern Medical

Clinical Trial. JAMA Oncol. 2020 Mar 1 2020;6(3):e193692.

[9]Tolaney SM, Guo H, Pernas S, et al. Seven-Year

Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab

Trial for Node-Negative, Human Epidermal Growth Factor

Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 Aug

1 2019;37(22):1868-1875.

[10]Pegram MD, Miles D, Tsui CK, Zong Y. HER2-

Overexpressing/Amplified Breast Cancer as a Testing Ground

for Antibody-Drug Conjugate Drug Development in Solid

Tumors. Clin Cancer Res. 2020 Feb 15 2020;26(4):775-786.

[11]Konecny GE, Pegram MD, Venkatesan N, et al.

Activity of the dual kinase inhibitor lapatinib (GW572016)

against HER-2-overexpressing and trastuzumab-treated breast

cancer cells. Cancer Res. 2006 Feb 1 2006;66(3):1630-1639.

[12]Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib

induces apoptosis in trastuzumab-resistant breast cancer cells:

effects on insulin-like growth factor I signaling. Mol Cancer

Ther. 2007 Feb 2007;6(2):667-674.

[13]de Bernardi A, Bachelot T, Larrouquere L. Longterm response to sequential anti-HER2 therapies including

trastuzumab-deruxtecan in a patient with HER2-positive

metastatic breast cancer with leptomeningeal metastases: a

case report and review of the literature. Front Oncol. 2023

2023;13:1210873.

[14 ]Xu B, Yan M, Ma F, et al. Py rotinib plu s

capecitabine versus lapatinib plus capecitabine for the treatment

of HER2-positive metastatic breast cancer (PHOEBE): a

multicentre, open-label, randomised, controlled, phase 3 trial.

Lancet Oncol. 2021 Mar 2021;22(3):351-360.

[15]Johnston S, Pippen JJ, Pivot X, et al. Lapatinib

combined with letrozole versus letrozole and placebo as

first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol. 2009 Nov 20

2009;27(33):5538-5546.

[16]Schlam I, Swain SM. HER2-positive breast cancer

and tyrosine kinase inhibitors: the time is now. NPJ Breast

Cancer. 2021 May 20 2021;7(1):56.

[17]Pereslete AM, Hughes ME, Martin AR, et al.

Analysis of HER2 expression changes from breast primary to

brain metastases and the impact of HER2-low expression on

overall survival. Neuro Oncol. 2024 Aug 30 2024.

[18]Steeg PS. The blood-tumour barrier in cancer

biology and therapy. Nat Rev Clin Oncol. 2021 Nov

2021;18(11):696-714.

[19]Bachelot T, Romieu G, Campone M, et al.

Lapatinib plus capecitabine in patients with previously

untreated brain metastases from HER2-positive metastatic

breast cancer (LANDSCAPE): a single-group phase 2 study.

Lancet Oncol. 2013 Jan 2013;14(1):64-71.

[20 ]Xu B, Yan M, Ma F, et al. Py rotinib plu s

capecitabine versus lapatinib plus capecitabine for the treatment

of HER2-positive metastatic breast cancer (PHOEBE): a

multicentre, open-label, randomised, controlled, phase 3 trial.

Lancet Oncol. 2021 Mar 2021;22(3):351-360.

[21]Murthy RK, Loi S, Okines A, et al. Tucatinib,

Trastuzumab, and Capecitabine for HER2-Positive Metastatic

Breast Cancer. N Engl J Med. 2020 Feb 13 2020;382(7):597-

609.

[22]Koster KL, Huober J, Joerger M. New antibodydrug conjugates (ADCs) in breast cancer-an overview of

ADCs recently approved and in later stages of development.

Explor Target Antitumor Ther. 2022 2022;3(1):27-36.


Refbacks

  • 当前没有refback。